Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of Belvarafenib for CNS Efficacy in BRAF-Altered Solid Tumors
KCT0012013Phase 2Recruiting
- Sponsor
- Hanmi Pharmaceutical
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Belvarafenib in brain neoplasm, brain metastases, Nonhematologic neoplasms, sponsored by Hanmi Pharmaceutical. Started Jun 2026; status: recruiting.
02
Drugs
Belvarafenib
03
Conditions
brain neoplasmbrain metastasesNonhematologic neoplasms
Beyond the preview
Go deeper on KCT0012013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0012013.